Berbamine

Berbamine’s marquee signal, and a genuinely sizeable preclinical literature. It binds the ATP pocket of CaMKIIγ — a kinase highly active in CML stem/progenitor cells but not normal HSCs — suppressing coactivated β-catenin/Stat3 networks ^{1Reference 1Gu Y et al. · 2012CaMKIIγ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamineView study →}, and it downregulates the bcr/abl fusion product to kill leukemia cells including imatinib-resistant and T315I-mutant CML clones in vitro and in xenografts ^{2,3Reference 2Xu R et al. · 2006Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activityView study →Reference 3Wei YL et al. · 2009In vitroBerbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivoView study →}. As a novel NF-κB inhibitor it arrests and apoptoses human myeloma cells ^{4Reference 4Liang Y et al. · 2009Berbamine, a novel nuclear factor-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cellsView study →}, and it targets CaMKII to suppress liver-cancer cells and cancer-initiating cells ^{5Reference 5Meng Z et al. · 2013Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase IIView study →}. Engineered berbamine derivatives (e.g. BBMD3) were built for greater Jak2/Stat3-inhibitory potency across leukemia, lymphoma, melanoma, glioblastoma and osteosarcoma models ^{6Reference 6Naik RR et al. · 2024Pharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus BerberisView study →}.

Gap: entirely preclinical (cell lines + rodent xenografts); no modern rigorous anticancer RCT of berbamine in any tumour type, and much of the solid-tumour potency belongs to the derivatives rather than the parent compound ^{1,6Reference 1Gu Y et al. · 2012CaMKIIγ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamineView study →Reference 6Naik RR et al. · 2024Pharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus BerberisView study →}.

Berbamine is the studied barberry bisBIQ for the heart. Reviewed cardiovascular actions include anti-arrhythmia, anti-myocardial-ischemia, vasodilation/blood-pressure lowering and antithrombotic effects ^{7Reference 7Zhang H et al. · 2005Zhang H, et al. (2005). [Progress of cardiovascular pharmacologic study on berbamine]. Zhongguo Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/16152843/View study →}, consistent with the calcium-antagonist/negative-inotropic signature of the bisBIQ class ^{8Reference 8Zhang JS et al. · 2002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →}. Its derivative N-methyl berbamine blocks both Cav1.2 (Ca²⁺) and Kv11.1/hERG (K⁺) currents to prolong the action potential as a multitarget antiarrhythmic ^{9Reference 9Duan X et al. · 2020A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currentsView study →}.

Gap: mechanistic/animal-level and largely older Chinese literature, with no controlled human antiarrhythmic or antihypertensive trials of the isolate; the hERG/Kv11.1 block is double-edged (antiarrhythmic and a proarrhythmic-liability signal) ^{8,9Reference 8Zhang JS et al. · 2002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →Reference 9Duan X et al. · 2020A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currentsView study →}.

Berbamine hydrochloride tablets have been marketed in China since the 1970s to prevent/treat leukopenia from radiotherapy/chemotherapy, promoting myeloid proliferation and leukocyte recovery ^{10Reference 10Zheng SZ et al. · 2012Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemiaView study →}. Its bisBIQ chemistry also carries the class’s anti-inflammatory/immunosuppressive reputation — e.g. suppression of the alveolar-macrophage respiratory burst ^{11Reference 11Chang HW et al. · 1992Inhibition of respiratory-burst activity in alveolar macrophages by bisbenzylisoquinoline alkaloidsView study →} — and it was implicated (as a Berberis co-alkaloid) in the antipsoriatic activity of Mahonia aquifolium cream ^{12Reference 12Gulliver WP · 2005Clinical trialA report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experienceView study →}, with NF-κB inhibition the shared thread back to the anticancer story ^{4Reference 4Liang Y et al. · 2009Berbamine, a novel nuclear factor-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cellsView study →}.

Gap: the leukopenia indication rests on older, largely non-randomised Chinese clinical/regulatory practice, not a modern RCT; the antipsoriatic role is within a whole-plant cream, not isolated berbamine ^{10,12Reference 10Zheng SZ et al. · 2012Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemiaView study →Reference 12Gulliver WP · 2005Clinical trialA report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experienceView study →}.